Analyst Derek Archila of Wells Fargo reiterated a Buy rating on Rhythm Pharmaceuticals (RYTM – Research Report), retaining the price target of $91.00.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Derek Archila has given his Buy rating due to a combination of factors that highlight the potential for Rhythm Pharmaceuticals to achieve significant growth. One of the key drivers is the anticipated data from the bivamelagon and RM-718 programs, expected in the second half of 2025. These programs are crucial as they target hypothalamic obesity, a condition with a growing prevalence, and successful proof of concept could propel the stock price significantly higher.
Additionally, despite a slight revenue miss in the first quarter of 2025 due to inventory dynamics, the underlying patient growth remains strong, and international revenues are increasing. The company’s plans to meet with the FDA and file for regulatory approvals in both the US and international markets further bolster confidence in its future prospects. With a solid cash runway extending into 2027 and positive market performance year-to-date, Archila sees a promising outlook for Rhythm Pharmaceuticals, supporting his Buy rating.
In another report released yesterday, Needham also reiterated a Buy rating on the stock with a $72.00 price target.